ERICOM Trial

  • Research type

    Research Study

  • Full title

    Determining the role of Endothelin in Microcirculatory Function in Myocardial Ischaemia

  • IRAS ID

    277281

  • Contact name

    Ahmed Farouk Mohamed Elamin

  • Contact email

    afmelamin@gmail.com

  • Sponsor organisation

    Liverpool University Hospitals

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    It is already known that a subset of patients with a clinical syndrome of angina and significant epicardial coronary disease also have significant microvascular dysfunction. Second, a subset of patients with a clinical syndrome of angina but without significant epicardial stenosis have significantly increased microvascular resistance and this correlates with perfusion abnormalities assessed by Cardiac perfusion imaging.\n\nFrom our literature review, no one has previously looked into the relationship between Microvascular Resistance and Endothelin.\n\nWe are planning to investigate the relationship between Endothelin and coronary microvascular resistance using non-invasive and invasive techniques. We are planning to confirm Microvascular disease using the myocardial perfusion reserve index (MPRI) measured by cardiac MRI, and index of microvascular resistance (IMR) via invasive coronary angiography, and then block Endothelin receptors using ETA blockers ETA antagonists for 1 month prior to repeating MPRI measurements and see if the intervention (ETA antagonists) do alter microvascular resistance or not.\n\nAlso, we will check Endothelin blood levels prior to giving the study subjects the new treatment; Endothelin receptor antagonists (ETA). \n\nPatients will be recruited from our rapid access chest pain clinic. They will only be included if they have non-obstructive coronary artery disease. \n\nOur sample size is estimated at 45, Participants will be then given ETA antagonists for 4 weeks. Repeat MPRI measurements will then take place to test our hypothesis. \n\nWe believe our study might open new doors for Phase 3 and 4 trials for ETA for the management of Angina.\n

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    22/SC/0424

  • Date of REC Opinion

    23 Dec 2022

  • REC opinion

    Further Information Favourable Opinion